DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Email from SurveyClub
March 4, 2019

The Department of Health has been made aware of an email sent to physicians from SurveyClub. Please click here for more information. Continue reading


REMINDER – Submit Statutorily Required Documentation to Board!
February 20, 2019

Medical Marijuana Use Registry fields for qualifying condition (k) do not comply with statutory and rule requirements. Submit form to board within 14-days of certification date. Continue reading